Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation
Affiliations: Ninth Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, P.R. China, Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China
- Published online on: November 1, 2011 https://doi.org/10.3892/mmr.2011.652
- Pages: 351-356
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
Research into the evasion of drug resistance and adverse effects is highly significant and urgent in the clinic. Therefore, accumulating studies have focused on the development of novel target‑specific molecules related to drug resistance, and the establishment of rational therapeutic approaches. Currently, studies have shown that NF-κB activation may play an essential role in the development of chemotherapy resistance in carcinoma cells. Paeoniﬂorin, a principal bioactive component of the root of Paeonia lactiﬂora Pall., has been reported to exhibit various pharmacological effects. In the present study, we reported for the first time that paeoniflorin at non-toxic concentrations may effectively modulate multidrug resistance (MDR) of the human gastric cancer cell line SGC7901/vincristine (VCR) via the inhibition of NF-κB activation and, at least partly, by subsequently downregulating its target genes MDR1, BCL-XL and BCL-2.